Relay Therapeutics, Inc. (RLAY) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | after close | 35 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Mon, May 5, 2025 | after close | 35 | 8-K |
| Q4 FY2024 | Wed, Feb 26, 2025 | after close | 57 | 8-K |
What they guided beta
| Q3 FY2026 | "Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition; Relay to hold conference call to discuss data and provide regulatory update Shannon Campbell to lead commercial preparations for zovegalisib in breast cancer and vascular anomalies Announced second vascular anomalies program for mutant-selective TIE2 inhibitor Approximately $849 million in cash, cas" exhibit |
| Q3 FY2026 | "The company expects its current cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2029." exhibit |
| Q1 FY2026 | "FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced patients at ESMO TAT, demonstrating 11.1-month median PFS with similar efficacy in kinase and non-kinase mutations Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027 Initiated Phase 1/2 trial of RLY-8161, a NRAS-selective mol" exhibit |
| Q1 FY2026 | "Announced clinical data for zovegalisib plus atirmociclib triplet combination, plans for frontline breast cancer study, and clinical supply agreement with Pfizer o Compelling efficacy and tolerability data presented for zovegalisib triplet in median third-line (3L) patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer o 44% objective response rate (ORR) reported in heavily pre-treated CDK4/6-experienced patients (median 3L) at unoptimized doses and ORR was similar across kinase and non-kinase PIK3CA mutations o Adverse events were consistent with those previously reported by each mol" exhibit |
| Q1 FY2026 | "The company expects its current cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2029." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RLAY
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RLAY
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/RLAY/"><img src="https://veritasdata.dev/embed/RLAY.svg" alt="RLAY earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/RLAY/)
Script
<script async src="https://veritasdata.dev/embed/RLAY.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RLAY"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.